Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (341-350 of 391) with videos related to

Pageof 40
Sort By:
Neurology|October 6, 2021
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisSteve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Neurology|April 21, 2021
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple SclerosisWei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Pageof 40

Showing results (341-350 of 391) with videos related to

Sort By:
Pageof 40
Neurology|October 6, 2021
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisSteve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 5, 2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosisChunrong Tao, Steve Simpson, Ingrid van der Mei, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Neurology|April 21, 2021
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple SclerosisWei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Pageof 40